Novo Nordisk Sees Retail Buying Despite Wall Street Cuts

Mitrade
Updated
coverImg
Source: DepositPhotos

Insights – Shares of leading weight-loss drugmaker Novo Nordisk plunged after disappointing results from its latest weight-loss drug trial. Despite analysts slashing their price targets, retail investors flooded into the stock with massive buy-the-dip activity.  


According to data from Vanda Research, retail inflows into Novo Nordisk surged 32-fold on Friday, December 20. The single-day net inflow jumped from $490,000 the previous day to $15.6 million.  


Marco Iachini, Senior Vice President at Vanda Research, noted that retail investors tend to buy the dip, particularly in popular stocks, and added that they would continue doing so until the strategy ceased to be effective.


Novo Nordisk’s December 20 trial results revealed that its next-generation weight-loss drug, CagriSema, achieved only a 22.7% weight loss effect after eight weeks of treatment, falling short of the market expectation of 25%.  


The company’s previous flagship weight-loss drug, Wegovy, had set high standards, and Novo Nordisk had hoped CagriSema would outperform its main competitor, Eli Lilly’s (LLY.US) Zepbound. However, the underwhelming trial results sent Novo Nordisk shares tumbling 17.83% on the day, while Eli Lilly’s stock ended a multi-day decline, rising 1.35%.  


Following the trial results, Wall Street analysts sharply lowered their price targets for Novo Nordisk.BMO Capital** cut its target from $156 to $105.  TD Cowen** reduced its target from $155 to $105.  Jefferies downgraded its target to $81.50 and maintained a "Sell" rating.  


As of the latest close, Novo Nordisk shares traded at $87.37, representing a year-to-date decline of 15.54%.  




* The content presented above, whether from a third party or not, is considered as general advice only.  This article should not be construed as containing investment advice, investment recommendations, an offer of or solicitation for any transactions in financial instruments.

goTop
quote
Do you find this article useful?
Related Articles
placeholder
Net Profit Doubles, Yet Stock Plummets—Is Amazon’s Q4 Earnings Report Really That Bad?TradingKey - On Thursday, February 7, tech giant Amazon (AMZN.US) released a mixed Q4 2024 earnings report after the market close. While revenue and profits exceeded expectations, disappointing guidan
Author  TradingKey
11 hours ago
TradingKey - On Thursday, February 7, tech giant Amazon (AMZN.US) released a mixed Q4 2024 earnings report after the market close. While revenue and profits exceeded expectations, disappointing guidan
placeholder
Is a Stock Market Crash Looming? Here's What I'm Doing to Protect My Investments Just in Case.While the stock market is still surging right now, investor sentiment may be taking a turn. Around 34% of U.S. investors feel "bearish" about the next six months, according to a we
Author  The Motley Fool
Yesterday 09: 45
While the stock market is still surging right now, investor sentiment may be taking a turn. Around 34% of U.S. investors feel "bearish" about the next six months, according to a we
placeholder
2 Popular AI Stocks to Sell Before They Fall 65% and 73%, According to Certain Wall Street AnalystsPalantir Technologies (NASDAQ: PLTR) and Tesla (NASDAQ: TSLA) were two of the most popular stocks among retail investors last year as measured by net inflows. But most Wall Street
Author  The Motley Fool
Feb 05, Wed
Palantir Technologies (NASDAQ: PLTR) and Tesla (NASDAQ: TSLA) were two of the most popular stocks among retail investors last year as measured by net inflows. But most Wall Street
placeholder
AMD Reports Record Q4 Revenue, Shares Plunge 9% on Data Center MissAMD, a global semiconductor giant, saw its stock price fluctuate dramatically after releasing its Q4 2024 earnings report, despite surpassing consensus estimates on both the top and bottom lines. The
Author  TradingKey
Feb 05, Wed
AMD, a global semiconductor giant, saw its stock price fluctuate dramatically after releasing its Q4 2024 earnings report, despite surpassing consensus estimates on both the top and bottom lines. The
placeholder
Microsoft Shares Slip on "Soft" Azure Revenue. Is This a Buying Opportunity in the Stock?Microsoft (NASDAQ: MSFT) shares fell after revenue from its Azure cloud computing platform came in at the low end of its prior guidance, although the unit continues to be company's
Author  The Motley Fool
Feb 04, Tue
Microsoft (NASDAQ: MSFT) shares fell after revenue from its Azure cloud computing platform came in at the low end of its prior guidance, although the unit continues to be company's